Literature DB >> 21619943

Immune-mediated CNS diseases: a review on nosological classification and clinical features.

Uwe K Zettl1, Olaf Stüve, Robert Patejdl.   

Abstract

The immune-mediated diseases of the central nervous system (CNS) cover a wide range of clinical manifestations. Over the last years, considerable efforts have been made to establish a nosologic concept based upon distinctive pathophysiological characteristics of the single diseases. We describe the historically defined entities of immune-mediated diseases that primarily, but not exclusively, are affecting myelin structures. These include very rare entities as Schilder's, Balo's and Marburg's disease or the chronic and relapsing types of optic neuritis, for which evidence based paradigms still are virtually missing. In other, slightly more frequent diseases as neuromyelitis optica (NMO), advances in the concepts of specific biological features have been achieved and are beginning to transform into changes in clinical concepts. Acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) are by far the most frequent entities in this group and thus the only ones for which extensive empirical data on disease biology and evidence based clinical management strategies exist by now. For the most important entities, clinical features and therapeutic approaches are reviewed on the basis of current evidence. The results of basic science studies are assessed for their implications in nosological classification.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 21619943     DOI: 10.1016/j.autrev.2011.05.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  38 in total

1.  Headache in the course of multiple sclerosis: a prospective study.

Authors:  Marcel Gebhardt; Peter Kropp; Frank Hoffmann; Uwe K Zettl
Journal:  J Neural Transm (Vienna)       Date:  2018-11-30       Impact factor: 3.575

Review 2.  Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported.

Authors:  Axel Petzold; Gordon T Plant
Journal:  J Neurol       Date:  2013-05-23       Impact factor: 4.849

3.  High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.

Authors:  Luisa Roch; Michael Hecker; Jörg Friess; Ines Charlotte Angerer; Dirk Koczan; Brit Fitzner; Ina Schröder; Kristin Flechtner; Hans-Jürgen Thiesen; Stefanie Meister; Alexander Winkelmann; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2016-09-08       Impact factor: 5.590

Review 4.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

5.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 6.  [Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].

Authors:  Alexander Winkelmann; Micha Löbermann; Uwe K Zettl
Journal:  Nervenarzt       Date:  2019-12       Impact factor: 1.214

Review 7.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 8.  Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.

Authors:  Uwe K Zettl; Paulus Rommer; Petra Hipp; Robert Patejdl
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

Review 9.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.